4,712 reports of this reaction
1.7% of all NAPROXEN reports
#10 most reported adverse reaction
DIZZINESS is the #10 most commonly reported adverse reaction for NAPROXEN, manufactured by ANI Pharmaceuticals, Inc.. There are 4,712 FDA adverse event reports linking NAPROXEN to DIZZINESS. This represents approximately 1.7% of all 280,499 adverse event reports for this drug.
NAPROXEN has an overall safety score of 85 out of 100. Patients taking NAPROXEN who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for NAPROXEN, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for NAPROXEN:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 4,712 FDA reports for NAPROXEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 1.7% of all adverse event reports for NAPROXEN, making it a notable side effect.
If you experience dizziness while taking NAPROXEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.